Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, describes and outlines the findings of a Phase II study investigating the efficacy of acalabrutinib, lenalidomide and rituximab (ALR) as triplet therapy for patients with treatment-naïve mantle cell lymphoma (MCL). The study was composed of two phases, with patients achieving response in the induction phase proceeding to the maintenance part of the trial. Dr Ruan explains that molecular measurable residual disease (MRD) analysis was performed during the study and patients who achieved MRD negative complete remission (CR) had the option to de-escalate their treatment intensity. Overall, results demonstrated that the triplet combination was well tolerated in this patient population, with a very encouraging response rate achieved. In regards to safety, all adverse events (AEs) observed were manageable, and MRD negativity was also achieved in most of the patients during the trial. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть